Kristen Lauing to Glioblastoma
This is a "connection" page, showing publications Kristen Lauing has written about Glioblastoma.
Connection Strength
1.384
-
Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence. Clin Cancer Res. 2023 12 01; 29(23):4973-4989.
Score: 0.191
-
Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma. Clin Cancer Res. 2021 12 01; 27(23):6514-6528.
Score: 0.164
-
Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. Clin Cancer Res. 2020 10 01; 26(19):5232-5245.
Score: 0.150
-
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies. Front Immunol. 2020; 11:1185.
Score: 0.150
-
Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017). Oncoimmunology. 2019; 8(3):1548242.
Score: 0.135
-
IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clin Cancer Res. 2018 06 01; 24(11):2559-2573.
Score: 0.128
-
Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. Clin Cancer Res. 2017 Nov 01; 23(21):6650-6660.
Score: 0.123
-
Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma. Brain Behav Immun. 2017 May; 62:24-29.
Score: 0.119
-
Advanced age negatively impacts survival in an experimental brain tumor model. Neurosci Lett. 2016 Sep 06; 630:203-208.
Score: 0.115
-
The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. J Clin Neurosci. 2015 Dec; 22(12):1964-8.
Score: 0.108